5 Biotech Stocks with Biggest Upside

2. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Average Target Price: $89.91

Potential Upside: 136.4%

Number of Hedge Fund Holders: 33

Value of Hedge Fund Holdings: $514,878,820

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a Novato, California-based biotech company founded in 2010 that is focused on developing therapeutics to treat rare or ultra-rare genetic diseases.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has achieved success once as its lead product, Crysvita (burosumab), was approved by the FDA in 2018 for the treatment of X-linked hypophosphatemia (XLH), a rare genetic bone disease. In a research report issued to investors on August 4, Jeffrey Hung at Morgan Stanley maintained an Overweight rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock and reiterated a target price of $95.